CN104367569A - Nano coenzyme Q10 oral liquid - Google Patents
Nano coenzyme Q10 oral liquid Download PDFInfo
- Publication number
- CN104367569A CN104367569A CN201410616472.XA CN201410616472A CN104367569A CN 104367569 A CN104367569 A CN 104367569A CN 201410616472 A CN201410616472 A CN 201410616472A CN 104367569 A CN104367569 A CN 104367569A
- Authority
- CN
- China
- Prior art keywords
- coenzyme
- nanometer
- oral liquid
- emulsion
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a nano coenzyme Q10 oral liquid, comprising the following raw materials in percentage by weight: 0.01%-20% of a nano coenzyme Q10 emulsion, 0.001%-20% of functional additive, 1%-40% of polymer sugar and 50%-98% of water, wherein the nano coenzyme Q10 emulsion is formed in manners of cladding coenzyme Q10 by phospholipid to form nano coenzyme Q10 with a core-shell structure, and then dispersing into a water solution of glycerol; the particle size of the nano coenzyme Q10 emulsion is 1-200nm; the coenzyme Q10 accounts for 0.5%-10% of the nano coenzyme Q10 emulsion; and the functional additive is one or more of amino acid and vitamin. Through the manner, according to the nano coenzyme Q10 oral liquid disclosed by the invention, compared with the prior art, the photostability of the coenzyme Q10 is improved; the oral biological availability of the coenzyme Q10 is increased; and the coenzyme Q10 can be well utilized.
Description
Technical field
The present invention relates to biological technical field, particularly relating to a kind of take coenzyme Q10 as the nanometer oral liquid of active component.
Background technology
Coenzyme Q10 (CoQ10) is a kind of quinone cyclics, has long isoprene side chains, is soluble in chloroform, benzene and carbon tetrachloride, is dissolved in acetone, petroleum ether and ether, is slightly soluble in ethanol, water insoluble and methanol.The biological activity of coenzyme Q10 mainly comes from the redox characteristic of its quinone ring and the physicochemical property of its side chain.Coenzyme Q10 is the Natural antioxidant and the cellular metabolism activator of cell self generation, the effect having the integrity of protection & restoration biofilm structure, stabilising membrane current potential and strengthen immunoreation, resist myocardial ischemia.Coenzyme Q10 can increase cardiac output, reduces Peripheral resistance, contributes to anti-heart failure effect, and the synthesis of aldosterone is had to inhibitory action with secretion and disturbs it to the effect of renal tubules.Coenzyme Q10 can also make peripheral vascular resistance decline, the nutrition of human activin cell and cellular energy, has and improves body immunity, enhancing antioxidation, slow down aging and enhancing human activity.In addition, also have adriamycin induced cardiotoxicity and protect the liver wait effect, apply widely.But coenzyme Q10 easily decomposes by illumination, and oral bioavailability rate is low.
Summary of the invention
The technical problem that the present invention mainly solves is to provide a kind of nanometer coenzyme Q 10 oral liquid, and this oral liquid has that stability is high, bioavailability advantages of higher.
For solving the problems of the technologies described above, the technical scheme that the present invention adopts is: provide a kind of nanometer coenzyme Q 10 oral liquid, the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 0.01%-20%, functional additive 0.001%-20%, polymerization sugar 1%-40%, water 50%-98%, wherein said nanometer coenzyme Q10 emulsion is that phospholipid parcel coenzyme Q10 forms the nanometer coenzyme Q10 with nucleocapsid structure, described nanometer coenzyme Q10 redispersion is formed in the aqueous solution of glycerol, described nanometer coenzyme Q10 emulsion particle diameter is 1-200nm, the mass percent that described coenzyme Q10 accounts for nanometer coenzyme Q10 emulsion is 0.5%-10%, described functional additive is aminoacid, one or more in vitamin.
In a preferred embodiment of the present invention, also comprise stabilizing agent in the component of described oral liquid, the percentage by weight that described stabilizing agent accounts in described nanometer coenzyme Q 10 oral liquid is 0.1%-5%.
In a preferred embodiment of the present invention; described aminoacid is lysine, phenylalanine, methionine, leucine, isoleucine, valine, threonine, tryptophan, histidine, arginine, one or more in glycine, serine, cysteine, tyrosine, glutamic acid, glutamine, aspartic acid, agedoite, proline, alanine, taurine, collagen protein.
In a preferred embodiment of the present invention, described vitamin is one or more in vitamin A and derivant, vitamin E and derivant thereof, vitamin D and derivant thereof, vitamin B, pantothenic acid, folic acid, inositol.
In a preferred embodiment of the present invention, described stabilizing agent is one or more the mixture in Polyethylene Glycol caprylic/capric glyceride, polyglyceryl-isostearate, polyglycerol acrylate, polyoxyethylene hydrogenated Oleum Ricini and octadecanoic acid ester of polyethylene glycol, polyoxyethylene sorbitol monostearate, polyoxyethylene sorbitan monolaurate, methylcellulose and derivant, cyclodextrin and derivant thereof.
In a preferred embodiment of the present invention, described polymerization sugar is one or more in oligofructose, oligomeric isomaltose, oligomeric xylose, oligomeric galactose, polydextrose.
In a preferred embodiment of the present invention, described phospholipid is one or more in soybean lecithin, Ovum Gallus domesticus Flavus lecithin, cephalin, sphingomyelins.
In a preferred embodiment of the present invention, the percentage by weight that described nanometer coenzyme Q10 emulsion accounts in described nanometer coenzyme Q 10 oral liquid is 0.1%-10%, and the percentage by weight that described polymerization sugar accounts in described nanometer coenzyme Q 10 oral liquid is 5%-30%.
In a preferred embodiment of the present invention, described nanometer coenzyme Q10 emulsion particle diameter is 20-100nm, and the mass percent that described coenzyme Q10 accounts for nanometer coenzyme Q10 emulsion is 1%-5%.
In a preferred embodiment of the present invention, the component of described oral liquid also comprises sweeting agent, described sweeting agent is one or more in cyclamate, sweetener, acesulfame potassium, sucralose, xylitol, maltose alcohol, the component of described oral liquid also comprises antiseptic, described antiseptic is one or more in benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, ethylparaben, and the component of described oral liquid also comprises essence.
The invention has the beneficial effects as follows: nanometer coenzyme Q 10 oral liquid of the present invention, this oral liquid compared with prior art improves the light stability of coenzyme Q10, adds the oral bioavailability rate of coenzyme Q10, and coenzyme Q10 can be made well to be utilized.
Detailed description of the invention
Be clearly and completely described to the technical scheme in the embodiment of the present invention below, obviously, described embodiment is only a part of embodiment of the present invention, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making other embodiments all obtained under creative work prerequisite, belong to the scope of protection of the invention.
Contain the nanometer coenzyme Q10 emulsion that mass percent is 0.01%-20% in nanometer coenzyme Q 10 oral liquid in the present invention, preferred mass percent is 0.1%-10%.Described nanometer coenzyme Q10 emulsion is the nanometer coenzyme Q10 that phospholipid is wrapped in that coenzyme Q10 formation has nucleocapsid structure, and described nanometer coenzyme Q10 redispersion is formed in the aqueous solution of glycerol.Described nanometer coenzyme Q10 emulsion particle diameter is 1-200nm, is preferably 20-100nm.The mass percent that described coenzyme Q10 accounts for nanometer coenzyme Q10 emulsion is 0.5%-10%, is preferably 1%-5%.Described phospholipid is one or more the mixture in soybean lecithin, Ovum Gallus domesticus Flavus lecithin, cephalin, sphingomyelins.A kind of preparation method of described nanometer coenzyme Q10 emulsion can refer to the phase transition temperature method in " cosmetic chemistry and Technology complete works ", and another kind of preparation method can refer to the high pressure homogenization method in Chinese patent 200710304523.5.
Other functional additive not comprising nanometer coenzyme Q10 emulsion containing 0.001%-20% in nanometer coenzyme Q 10 oral liquid of the present invention, described functional additive is one or more the mixture in aminoacid and vitamin, described aminoacid is lysine, phenylalanine, methionine, leucine, isoleucine, valine, threonine, tryptophan, histidine, arginine, glycine, serine, cysteine, tyrosine, glutamic acid, glutamine, aspartic acid, agedoite, proline, alanine, taurine, one or more in collagen protein, described vitamin is vitamin A and derivant thereof, vitamin E and derivant thereof, vitamin D and derivant thereof, vitamin B, pantothenic acid, folic acid, one or more in inositol.
Containing mass percent in nanometer coenzyme Q 10 oral liquid of the present invention is the polymerization sugar of 1%-40%, preferred mass percent is 5%-30%, and described polymerization sugar is one or more the mixture in oligofructose, oligomeric isomaltose, oligomeric xylose, oligomeric galactose, polydextrose.
Containing mass percent in nanometer coenzyme Q 10 oral liquid of the present invention is the water of 50%-98%.
Nanometer coenzyme Q 10 oral liquid of the present invention can be also the stabilizing agent of 0.1%-5% containing mass percent, and described stabilizing agent is one or more the mixture in Polyethylene Glycol caprylic/capric glyceride, polyglyceryl-isostearate, polyglycerol acrylate, polyoxyethylene hydrogenated Oleum Ricini and octadecanoic acid ester of polyethylene glycol, polyoxyethylene sorbitol monostearate, polyoxyethylene sorbitan monolaurate, methylcellulose and derivant, cyclodextrin and derivant thereof.
Nanometer coenzyme Q 10 oral liquid of the present invention also can containing appropriate sweeting agent, and described sweeting agent is one or more the mixture in cyclamate, sweetener, acesulfame potassium, sucralose, xylitol, maltose alcohol.
Nanometer coenzyme Q 10 oral liquid of the present invention also can containing appropriate antiseptic, described antiseptic is one or more mixture in benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, ethylparaben, and consumption uses according to GB2760 " food additive use sanitary standard " regulation.
Nanometer coenzyme Q 10 oral liquid of the present invention also can containing appropriate essence.
Following examples are further elaborated scope of the present invention, and conveniently following single composition mixes by oral liquid technology of preparing.
Embodiment one:
A kind of nanometer coenzyme Q 10 oral liquid is provided; the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 0.01%, taurine 0.001%, oligofructose 4%, potassium sorbate 0.04%, cyclamate 0.01%, essence 0.05%, add water to 100%.
Embodiment two:
There is provided a kind of nanometer coenzyme Q 10 oral liquid, the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 10%, taurine 5%, oligofructose 20%, potassium sorbate 0.04%, acesulfame potassium 0.01%, essence 0.05%, add water to 100%.
Embodiment three:
A kind of nanometer coenzyme Q 10 oral liquid is provided; the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 10%, taurine 20%, oligofructose 30%, potassium sorbate 0.04%, cyclamate 0.01%, essence 0.05%, add water to 100%.
Embodiment four:
A kind of nanometer coenzyme Q 10 oral liquid is provided; the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 20%, taurine 5%, pantothenic acid 2.5%, oligofructose 40%, potassium sorbate 0.04%, cyclamate 0.01%, essence 0.05%, add water to 100%.
Embodiment five:
A kind of nanometer coenzyme Q 10 oral liquid is provided; the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 5%, taurine 0.5%, folic acid 1%, oligofructose 20%, potassium sorbate 0.04%, cyclamate 0.01%, essence 0.05%, add water to 100.
Embodiment six:
A kind of nanometer coenzyme Q 10 oral liquid is provided; the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 6%, taurine 1%, proline 0.5%, vitamin B 1.2%, oligofructose 20%, sodium benzoate 0.04%, cyclamate 0.01%, essence 0.05%, add water to 100.
Embodiment seven:
A kind of nanometer coenzyme Q 10 oral liquid is provided, the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 5%, vitamin E 0.5%, collagen protein 2.5%, polyoxyethylene hydrogenated Oleum Ricini 1%, oligofructose 20%, potassium sorbate 0.04%, cyclamate 0.01%, essence 0.05%, add water to 100%.
The foregoing is only embodiments of the invention; not thereby the scope of the claims of the present invention is limited; every utilize description of the present invention to do equivalent structure or equivalent flow process conversion; or be directly or indirectly used in other relevant technical field, be all in like manner included in scope of patent protection of the present invention.
Claims (10)
1. a nanometer coenzyme Q 10 oral liquid, it is characterized in that, the Ni lead-free solder alloy of described oral liquid is: nanometer coenzyme Q10 emulsion 0.01%-20%, functional additive 0.001%-20%, polymerization sugar 1%-40%, water 50%-98%, wherein said nanometer coenzyme Q10 emulsion is that phospholipid parcel coenzyme Q10 forms the nanometer coenzyme Q10 with nucleocapsid structure, described nanometer coenzyme Q10 redispersion is formed in the aqueous solution of glycerol, described nanometer coenzyme Q10 emulsion particle diameter is 1-200nm, the mass percent that described coenzyme Q10 accounts for nanometer coenzyme Q10 emulsion is 0.5%-10%, described functional additive is aminoacid, one or more in vitamin.
2. nanometer coenzyme Q 10 oral liquid according to claim 1, is characterized in that, also comprise stabilizing agent in the component of described oral liquid, and the percentage by weight that described stabilizing agent accounts in described nanometer coenzyme Q 10 oral liquid is 0.1%-5%.
3. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2; it is characterized in that; described aminoacid is lysine, phenylalanine, methionine, leucine, isoleucine, valine, threonine, tryptophan, histidine, arginine, one or more in glycine, serine, cysteine, tyrosine, glutamic acid, glutamine, aspartic acid, agedoite, proline, alanine, taurine, collagen protein.
4. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2, it is characterized in that, described vitamin is one or more in vitamin A and derivant, vitamin E and derivant thereof, vitamin D and derivant thereof, vitamin B, pantothenic acid, folic acid, inositol.
5. nanometer coenzyme Q 10 oral liquid according to claim 2, it is characterized in that, described stabilizing agent is one or more the mixture in Polyethylene Glycol caprylic/capric glyceride, polyglyceryl-isostearate, polyglycerol acrylate, polyoxyethylene hydrogenated Oleum Ricini and octadecanoic acid ester of polyethylene glycol, polyoxyethylene sorbitol monostearate, polyoxyethylene sorbitan monolaurate, methylcellulose and derivant, cyclodextrin and derivant thereof.
6. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2, is characterized in that, described polymerization sugar is one or more in oligofructose, oligomeric isomaltose, oligomeric xylose, oligomeric galactose, polydextrose.
7. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2, is characterized in that, described phospholipid is one or more in soybean lecithin, Ovum Gallus domesticus Flavus lecithin, cephalin, sphingomyelins.
8. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2, it is characterized in that, the percentage by weight that described nanometer coenzyme Q10 emulsion accounts in described nanometer coenzyme Q 10 oral liquid is 0.1%-10%, and the percentage by weight that described polymerization sugar accounts in described nanometer coenzyme Q 10 oral liquid is 5%-30%.
9. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2, is characterized in that, described nanometer coenzyme Q10 emulsion particle diameter is 20-100nm, and the mass percent that described coenzyme Q10 accounts for nanometer coenzyme Q10 emulsion is 1%-5%.
10. nanometer coenzyme Q 10 oral liquid according to claim 1 and 2, it is characterized in that, the component of described oral liquid also comprises sweeting agent, described sweeting agent is one or more in cyclamate, sweetener, acesulfame potassium, sucralose, xylitol, maltose alcohol, the component of described oral liquid also comprises antiseptic, described antiseptic is one or more in benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, ethylparaben, and the component of described oral liquid also comprises essence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410616472.XA CN104367569A (en) | 2014-11-06 | 2014-11-06 | Nano coenzyme Q10 oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410616472.XA CN104367569A (en) | 2014-11-06 | 2014-11-06 | Nano coenzyme Q10 oral liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104367569A true CN104367569A (en) | 2015-02-25 |
Family
ID=52546934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410616472.XA Pending CN104367569A (en) | 2014-11-06 | 2014-11-06 | Nano coenzyme Q10 oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367569A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105166935A (en) * | 2015-09-01 | 2015-12-23 | 张伟 | Liquid preparation containing vitamin D3 and preparation method of liquid preparation |
| CN105286016A (en) * | 2015-11-10 | 2016-02-03 | 兰州天和生物催化技术有限公司 | Casein hydrolysate peptide food for phenylalanine metabolic disorders |
| CN113081962A (en) * | 2021-05-08 | 2021-07-09 | 上海英库商务咨询有限公司 | Drops for preventing heart diseases of human and mammals |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214197A (en) * | 2007-12-28 | 2008-07-09 | 清华大学 | Cozymase Q10 nano microcapsule emulsions and preparation and application thereof |
| CN101940564A (en) * | 2010-09-30 | 2011-01-12 | 杭州华东医药集团康润制药有限公司 | Water-soluble coenzyme Q10 combination and preparation method thereof |
-
2014
- 2014-11-06 CN CN201410616472.XA patent/CN104367569A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214197A (en) * | 2007-12-28 | 2008-07-09 | 清华大学 | Cozymase Q10 nano microcapsule emulsions and preparation and application thereof |
| CN101940564A (en) * | 2010-09-30 | 2011-01-12 | 杭州华东医药集团康润制药有限公司 | Water-soluble coenzyme Q10 combination and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张静: "辅酶Q10纳米微囊乳液体内代谢动力学研究和抗氧化研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 1, 15 December 2011 (2011-12-15) * |
| 王富济: "纳米辅酶Q10抗皮肤光老化及其抗氧化作用研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 4, 15 April 2011 (2011-04-15), pages 4 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105166935A (en) * | 2015-09-01 | 2015-12-23 | 张伟 | Liquid preparation containing vitamin D3 and preparation method of liquid preparation |
| CN105166935B (en) * | 2015-09-01 | 2018-08-31 | 张伟 | A kind of liquid preparation and preparation method thereof containing vitamine D3 |
| CN105286016A (en) * | 2015-11-10 | 2016-02-03 | 兰州天和生物催化技术有限公司 | Casein hydrolysate peptide food for phenylalanine metabolic disorders |
| CN113081962A (en) * | 2021-05-08 | 2021-07-09 | 上海英库商务咨询有限公司 | Drops for preventing heart diseases of human and mammals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010051541A3 (en) | Compositions containing delta-9-thc-amino acid esters and process of preparation | |
| CN104367569A (en) | Nano coenzyme Q10 oral liquid | |
| JP2010132639A (en) | Dna damage inhibitor and matrix metalloprotease-1 production inhibitor | |
| EP2471539B1 (en) | Transdermal composition of phosphatidylcholine and method for producing same | |
| BR112012000804B8 (en) | dry composition for mixing with water, aqueous solution, kit and unit dose composition for mixing with water | |
| ES2779749T3 (en) | Compositions comprising amino acids for use in the treatment of mucositis in patients with neoplasia who are undergoing radiotherapy and / or chemotherapy | |
| KR20130132496A (en) | Stabilizer of acetaminophen | |
| JP5781802B2 (en) | Topical skin preparation | |
| JP2011256166A (en) | Stable aqueous preparation | |
| JP2013227353A (en) | Milky lotion cosmetic | |
| CH707354A1 (en) | Pharmaceutical composition in the form of an oral suspension comprising a flavonoid moiety and xanthan gum. | |
| WO2017024953A1 (en) | Nimodipine water-soluble derivative, and preparation method and use thereof | |
| CA2995839A1 (en) | Pharmaceutical composition for administration to nasal mucosa | |
| JP2016108309A (en) | Cosmetic liquid and production method thereof | |
| ES2883956T3 (en) | Ophthalmic composition comprising lipoic acid and hyaluronic acid | |
| JP2004099564A (en) | Humectant cosmetic | |
| CA2857592C (en) | Composition based on ubidecarenone | |
| ES2665011T3 (en) | Pharmaceutical composition for the prevention and treatment of degenerative skin disorders especially caused by ionizing radiation | |
| JP2015089877A (en) | α LIPOIC ACID DERIVATIVE-CONTAINING VISCOUS FORMULATION | |
| JP2007254315A5 (en) | ||
| CN101278890A (en) | Self-emulsifying vitamin C preparation and method of preparing the same and application thereof | |
| JP2015010059A (en) | Pharmaceutical composition | |
| JP2008239508A (en) | alpha-LIPOIC ACID-CONTAINING TRANSPARENT AQUEOUS COSMETIC | |
| WO2017069128A1 (en) | Moisturizer and cosmetic containing same | |
| CN113633583B (en) | Oral care compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |
|
| RJ01 | Rejection of invention patent application after publication |